
Centessa Pharmaceuticals PLC
CNTANASDAQ NMS - GLOBAL MARKETKey Statistics
Open
—
Day High
—
Day Low
—
Prev. Close
$39.90
VolumeShares traded today.
1.11M
Avg. VolumeAverage daily volume.
—
Market CapTotal value of all shares = price × shares outstanding.
$6.17B
P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.
-22.57
Forward P/EP/E based on forecast next-year earnings.
—
P/B RatioPrice-to-Book: share price ÷ book value per share.
—
52W HighHighest price over the past 52 weeks.
$40.26
52W LowLowest price over the past 52 weeks.
$10.95
50D MAAverage closing price over the last 50 trading days.
$38.23
200D MAAverage closing price over the last 200 trading days.
$27.61
Dividend YieldAnnual dividend ÷ share price, as a %.
—
BetaVolatility vs the market. >1 = more volatile than the S&P 500.
—
Performance
1W
+0.3%1M
+0.8%6M
+37.4%YTD
+68.4%1Y
+197.5%About
Lixivaptan (VPA-985) is an orally-active, non-peptide, selective vasopressin V2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. As of December 2021, lixivaptan is in phase III clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lixivaptan for the treatment of ADPKD.
www.centessa.com/Company Facts
Similar stocks
Health CareSentiment
Latest News
Social Noise
Price Alerts
Loading…
Trade CNTA
Brokers available in your region (US)
Affiliate links — we may earn a commission. CFDs are risky.